The article presents the results of studies of subchronic oral toxicity in laboratory animals of the new veterinary drug Amoxiantar. The studies were carried out as part of a laboratory-experimental (preclinical) study of a medicinal product with the aim of introducing it into clinical veterinary practice. Our goal was to study the effect of Amoxiantar on the hematological and biochemical parameters of the blood of laboratory animals. Three experimental groups were formed, of which two experimental and one control, consisting of white outbred rats, 10 animals each. The drug was administered to animals daily intragastrically for 15 days, rats of the first experimental group at a dose of 150 mg/kg body weight, rats of the second group 15 mg/kg body weight, the control group was injected with distilled water. Blood was taken on the first and tenth days after the completion of the administration of the Amoxiantar preparation, on the 16th and 25th day of the experiment, respectively. Statistical processing of the results of the general clinical analysis of the blood of animals on the tenth day after the completion of the drug (25 days of the experiment) revealed monocytosis in the blood of the first and second experimental groups and leukocytosis in the first experimental group compared with the control group, however, these values were normal rat blood parameters. The revealed statistically significant differences, on the 25th day of the experiment, between the second experimental group and the control group in terms of AST, alkaline phosphatase and creatinine were clinically insignificant. During the 25th day of the subchronic experiment, the new veterinary drug Amoxiantar did not adversely affect the hematological and biochemical blood parameters of laboratory animals at doses of 15 and 150 mg/kg of animal body weight.
Read full abstract